DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES

流感疫苗类 AS01 合成佐剂系统 SAS 的开发

• 批准号: 10935776
• 负责人: DAVID BURKHART
• 金额: $ 174.44万
• 依托单位: INIMMUNE CORPORATION
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2028-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10935776
• 关键词: Adjuvant; Agonist; Antibodies; Antigens; Bacterial Vaccines; Chemistry; Collaborations; Contractor; Contracts; Cyclic GMP; Development; Drug Kinetics; Excretory function; Exhibits; Ferrets; Formulation; Generations; Head; Immune response; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B Virus; Lead; Metabolism; Modeling; Proteins; QS21; Recombinants; Safety; Saponins; System; T-Lymphocyte; TLR4 gene; Toxicology; Vaccine Adjuvant; Vaccines; Viral Vaccines; absorption; flu; immunogenicity; influenza virus vaccine; manufacture; novel; pre-clinical; scale up; seasonal influenza

Inimmune is developing a second generation synthetic AS01-like adjuvant system (termed SAS), by partnering our novel fully synthetic TLR4 agonist INI-2002, with a semi-synthetic saponin for use in vaccines. Pre-clinically, SAS has demonstrated excellent antibody and T-cell immune responses when paired with a split flu antigen. This versatile vaccine adjuvant is expected to provide a significant enhancement to the immune response to both viral and bacterial vaccines while exhibiting a favorable safety profile. Under this contract, Inimmune, in collaboration with its subcontracting partners, will optimize, scale-up, and produce cGMP SAS in an effort to advance it to an IND submission.

Inimmune正在开发第二代合成AS 01样佐剂系统（称为SAS），通过将我们的新型全合成TLR 4激动剂INI-2002与用于疫苗的半合成皂苷合作。在临床前，SAS已经证明了与裂解流感抗原配对时具有优异的抗体和T细胞免疫应答。预期这种多用途疫苗佐剂显著增强对病毒和细菌疫苗的免疫应答，同时表现出有利的安全性特征。根据该合同，Inimmune将与其分包合作伙伴合作，优化，扩大和生产cGMP SAS，以推动其提交IND。